| HOME >> MEDICINE >> TECHNOLOGY |
ASCO Abstracts
For oral presentation
-- A Phase 1 dose escalation study of ARQ 197, a selective inhibitor of the c-Met receptor in patients with metastatic solid tumors
For publication in ASCO proceedings
-- A Phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma
-- A Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS)
AACR Abstracts
-- Pharmacokinetics of a novel PGA-ARQ 501 conjugate in mouse xenografts
-- Mass balance and characterization of the Metabolites of ARQ 501 ((beta)-lapachone), a checkpoint pathway activator in clinical development
-- Pharmacodynamic biomarkers for checkpoint pathway activator ARQ501 in a human colon xenograft model
-- Selective induction of necrotic cell death in cancer cells by (beta)-lapachone through activation of DNA damage response pathway
-- Evaluation of biomarkers for HGFR/c-Met inhibitor ARQ 197 in a human xenograft model
-- Functional chemogenomics approach to identify checkpoint pathway activators against cancer
-- Selective killing of cancer cells by activation of human checkpoint kinase 2
-- ARQ 197, a highly selective small molecule inhibitor of c-Met, inhibits invasive and metastatic growth of cancer cells
-- ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells
-- Broad spectrum anti-cancer activity of ARQ 197, a highly selective oral c-Met Inhibitor, in multiple xenograft models
-- Anti-metastatic activity of ARQ 197, a highly selective oral
small molecule inhibitor of c-Met,
'"/>